Related Experiment Video

Updated: Jun 27, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

[Computer simulations to support drug therapy in children]

André Breddemann1, Stephanie Läer

  • 1Institut für Klinische Pharmazie und Pharmakotherapie, Heinrich-Heine-Universität Düsseldorf, Universitästsstrasse 1, 40255 Düsseldorf.

Medizinische Monatsschrift Fur Pharmazeuten
|December 6, 2008
PubMed

Insights

Pediatric drug dosing requires age-appropriate adjustments due to developmental changes affecting drug behavior. Physiologically-based pharmacokinetic modeling aids in optimizing pediatric drug therapy and clinical trial design.

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Pediatric Pharmacology
  • Computational Biology

Context:

  • Human growth is non-linear, impacting drug absorption, distribution, metabolism, and excretion.
  • Age-dependent variations in body composition and organ function affect drug efficacy and safety.
  • Traditional dosing regimens may not be suitable for pediatric patients.

Purpose:

  • To highlight the importance of age-appropriate dosing in pediatric drug therapy.
  • To introduce physiologically-based pharmacokinetic (PBPK) modeling as a tool for pediatric drug development.
  • To demonstrate the benefits of simulation techniques in individualizing pediatric treatment.

Summary:

  • Physiologically-based pharmacokinetic modeling provides insights into age-dependent pharmacokinetic properties in pediatrics.
  • This approach facilitates clinical trial design and supports personalized drug treatment strategies.
  • An example illustrates improved patient outcomes using PBPK simulations for cidofovir treatment in a pediatric viral infection.

Impact:

  • Enhances the safety and effectiveness of drug therapy in children.
  • Enables more precise and individualized dosing for pediatric patients.
  • Accelerates the development of new drugs and optimizes existing treatments for pediatric populations.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...